Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy
Authors: Mieras L, Anthony R, van Brakel W, Bratschi MW, van den Broek J, Cambau E, Cavaliero A, Kasang C, Perera G, Reichman L, Richardus JH, Saunderson P, Steinmann P, Yew WW.
Source: Infect Dis Poverty. 2016 Jun 8;5(1):46.
Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in the first 2-3 years after receiving SDR. In countries where SDR is currently being implemented under routine programme conditions in defined areas, questions were raised by health authorities and professional bodies about the possible risk of inducing rifampicin resistance among the M. tuberculosis strains circulating in these areas. This issue has not been addressed in scientific literature to date. To produce an authoritative consensus statement about the risk that SDR would induce rifampicin-resistant tuberculosis, a meeting was convened with tuberculosis (TB) and leprosy experts. They concluded that SDR given to contacts of leprosy patients, in the absence of symptoms of active TB, poses a negligible risk of generating resistance in M. tuberculosis in individuals and at the population level.
An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++
The Development of a Mobile Application to Support Peripheral Health Workers to Diagnose and Treat People with Skin Diseases in Resource-Poor Settings
Towards a toolkit for cross-neglected tropical disease morbidity and disability assessment